Halozyme Therapeutics HALO Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's total costs & expenses?
- Halozyme Therapeutics (HALO) reported total costs & expenses of $192.19M in Q1 2026.
- How has Halozyme Therapeutics's total costs & expenses changed year-over-year?
- Halozyme Therapeutics's total costs & expenses increased by 55.8% year-over-year, from $123.33M to $192.19M.
- What is the long-term trend for Halozyme Therapeutics's total costs & expenses?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's total costs & expenses has grown at a 53.4% compound annual growth rate (CAGR), from $167.41M to $927.61M.
- What does total costs & expenses mean?
- Total costs and expenses represent the sum of all operating costs, including cost of revenue, R&D, SG&A, and other operating charges. This figure provides a comprehensive view of the total resources consumed to support the company's operations during a specific period. It is the primary denominator for evaluating overall operational cost control.